Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05925335
Other study ID # 2023YLK 21
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 11, 2023
Est. completion date June 11, 2025

Study information

Verified date June 2023
Source Xiamen Cardiovascular Hospital, Xiamen University
Contact Xiang Chen, Dr
Phone 18033997788
Email Seanchenx@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mitral valve disease is the most common structure heart disease, and surgical valve replacement is an important treatment for severe mitral valve disease. There are 2 types of valve often been used, mechanical or biological protheses valves. Mechanical valve requires lifelong use of anticoagulants and take the risk of bleeding through all lifetime, but bioprotheses valve do not..


Description:

Due to a massive shift from mechanical to bioprosthetic valves with finite longevity, increasing numbers of patients are presenting with bioprosthetic mitral valve degeneration. Mitral valve reoperation, the standard therapy for the bioprosthetic failure in the past, often entails high risk due to age, multiple comorbidities et al. TMVR is an emerging treatment for the patients with bioprosthetic failure at high risk for conventional mitral valve surgery. Recent studies from US and Europe have demonstrated the safety and efficacy of TMVR in this population. However, there are limited data regarding clinical outcomes after TMVR from Asia-Pacific region. To evaluate the safety and efficacy of TMVR using balloon-expandable valve among those patients with high risk for redo surgery and those who refuse redo surgery after shared decision making even they have less than high risk.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 11, 2025
Est. primary completion date July 11, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject had a degenerated surgical mitral bioprosthesis with at least moderate to severe mitral regurgitation or severe stenosis with echocardiographically derived mitral valve area (MVA) of =1.5 cm2 - Subjiect is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater. - Subject is at least 18 years old. - Heart team (including cardiac surgeon) agree on eligibility including assessment that transeptal, transcatheter mitral valve replacement (TsMVR) and redo surgical mitral valve replacement (rSMVR) are appropriate. - The study patient or the study patient's legal representative informed of the nature of the study, agreed to its provisions and provided written informed consent as approved by the Institutional Review Board (IRB) center. - The study Subject agreed to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which was conducted as a phone/clinic follow-up. Exclusion Criteria: - Subject was operable with the assessment of experienced Heart Team - Subject had evidence of an acute MI, percutaneous intervention, or a peripheral intervention =30 days prior to Portico ViV index procedure. - Subject had uncontrolled blood dyscrasias defined as: leukopenia (WBC<3,000 mm3), acute anemia (Hb <9 g/dL), or thrombocytopenia (platelet count <50,000 cells/mm³). - Subject was considered hemodynamically unstable at the time of the ViV procedure (requiring inotropic support or mechanical heart assistance) - Subject had severe ventricular dysfunction with left ventricular ejection fraction (LVEF) <20% as measured by resting echocardiogram. - Subject had imaging evidence of intracardiac mass, thrombus or vegetation. - Subject had an active peptic ulcer or has/had upper gastrointestinal (GI) bleeding =3 months prior to ViV index procedure. - Subject had a documented history of a cerebrovascular accident (CVA) or a transient ischemic attack (TIA) =6 months prior to index procedure. - Subject had active bacterial endocarditis or ongoing sepsis = 6 months prior to the index procedure. - Subject was unable to tolerate antiplatelet or anticoagulant therapy

Study Design


Intervention

Device:
Transseptal Transcatheter Mitral valve-in-valve Replacement
Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.

Locations

Country Name City State
China Yan Wang Xiamen Fujian

Sponsors (1)

Lead Sponsor Collaborator
Xiamen Cardiovascular Hospital, Xiamen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary all-cause mortality The rate in all-cause mortality will be calculated from 0 month to 12 months. 12 months
Primary Rate of New hospitalization for heart failure Hospitalization for valve-related symptoms or worsening congestive heart failure 12 months
Secondary Technical success Technical success was the primary safety endpoint at the time of patient exit from the cardiac catheterization laboratory, which was defined as the delivery and retrieval of the transcatheter delivery system being successful, the deployment of a single valve in the proper position in the mitral annulus, no need for surgery or additional reintervention, and the patient leaving the procedure room alive 24 hours
Secondary Procedure success Procedure success defiened as adequate performance of the THV with residual MR grade < 2 and mean MV gradient (MVG) < 10 mm Hg. 12 months
Secondary all-cause mortality The rate in all-cause mortality will be calculated from 0 month to 12 months. annual for five years
Secondary Rate of New hospitalization for heart failure Hospitalization for valve-related symptoms or worsening congestive heart failure annual for five years
Secondary Rate of myocardial infarction annual for five years
Secondary Rate of neurological events All stroke, transient ischemic attack (TIA) annual for five years
Secondary Rate of Structural Valve dysfunction as assessed by transthoracic echocardiography with residual MR grade > 2 and mean MV gradient (MVG) = 10 mm Hg. annual for five years
Secondary Clinical Benefit Endpoint Change in New York Heart Association (NYHA) functional classification from baseline 30 days, 6 months, 12 months, annual for five years]
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy